49,267
edits
Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
Prostate-specific antigen (view source)
Revision as of 16:09, 21 September 2025
, 16:09, 21 September 2025→Free serum PSA/total PSA
| Line 58: | Line 58: | ||
====Free serum PSA/total PSA==== | ====Free serum PSA/total PSA==== | ||
:Also ''PSA free-to-total ratio'' (abbreviated ''FTR''<ref name=pmid39607059>{{cite journal |authors=Sii S, Papa N, Yiu TW, Tempo J, Qu L, Perera M, Thompson I, Ischia J, Fleshner N, Smith E, Ranasinghe W, Bolton D, Woon DT |title=Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL |journal=BJU Int |volume=135 |issue=4 |pages=550–556 |date=April 2025 |pmid=39607059 |doi=10.1111/bju.16597 |url=}}</ref>) and ''PSA free/PSA ratio'' | :Also ''PSA free-to-total ratio'' (abbreviated ''FTR''<ref name=pmid39607059>{{cite journal |authors=Sii S, Papa N, Yiu TW, Tempo J, Qu L, Perera M, Thompson I, Ischia J, Fleshner N, Smith E, Ranasinghe W, Bolton D, Woon DT |title=Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL |journal=BJU Int |volume=135 |issue=4 |pages=550–556 |date=April 2025 |pmid=39607059 |doi=10.1111/bju.16597 |url=}}</ref>) and ''PSA free/PSA ratio'' | ||
* PSA in the serum can be found bound to protein or unbound (free).<ref>{{cite journal |authors=Cazanave Mora JM, Del Valle García R, Pérez López L, Bequer Ariza DC, Zulueta Rodríguez O, Melchor Rodríguez A, Hernández Pérez L, López Cisneros R, Arteaga Yera AL, Silva Cabrera E, Fernández Yero JL |title=Measurement of total and free prostate specific antigen (PSA) in human serum samples using an ultra-microanalytical system |journal=J Pharm Biomed Anal |volume=208 |issue= |pages=114470 |date=January 2022 |pmid=34798395 |doi=10.1016/j.jpba.2021.114470 |url=}}</ref> | |||
* High values of FTR have a lower risk of prostate cancer. | * High values of FTR have a lower risk of prostate cancer. | ||
** Modelling based on a cohort 406 men showed that: FTR ≤0.15 ~46% had prostate cancer versus FTR ≥0.20 ~22% had prostate cancer.<ref name=pmid39607059/> | ** Modelling based on a cohort 406 men showed that: FTR ≤0.15 ~46% had prostate cancer versus FTR ≥0.20 ~22% had prostate cancer.<ref name=pmid39607059/> | ||